LXEO Stock Forecast & Price Target

Lexeo Therapeutics is attractive because LX2006 in Friedreich ataxia cardiomyopathy has a largely de-risked Ph.1/2 dataset, a clear regulatory path, and a well-defined addressable population, supporting a positively skewed setup into pivotal data in 2H27. The emerging neurological signal and 12-month divergence from natural history could broaden differentiation, while strategic collaborations and the Mantle assets may help solve key gene therapy constraints around CNS delivery and redosing, expanding the total addressable market. Financially, the company reported $227.6mm of cash as of 31 March 2026, implying runway into 2028, and the thesis also benefits from LX2020’s optionality and FDA-aligned path forward.

Lexeo Therapeutics is viewed negatively because its AAV-based gene therapy platform remains highly exposed to clinical, regulatory, manufacturing, and safety setbacks, and the FDA could require longer, more capital-intensive pivotal trials that increase financing risk and dilution. Although LX2006 has shown encouraging data in 17 participants, including 18% to 23% mean LVMI reductions at 6 to 12 months and a statistically significant mFARS signal versus natural history, the results remain early, retrospective, and not yet sufficient to de-risk commercialization. Payer and reimbursement friction, competition from more convenient small-molecule or genetic rivals, and limited uptake in Friedreich ataxia and PKP2 could constrain the company’s long-term revenue potential and keep net cash value under pressure.